Dicerna has a chronic Hepatitis B drug development program, DCR-HBVS, in Phase 1 for which it partnered with Roche (OTCQX:RHHBY) last week, receiving an upfront $200 million payment and potential milestone payments that can approach $1.5 billion.
There also have connections to Eli Lily... a name which should be familiar to Kazia holders. Completely different biotech sector of course but shows there’s partners for early stage trials if results look interesting enough.
Theres more activity building in biotech generally which is good to see and I do think we are in the map with major Pharma just not so much in the investment community - hopefully our pending news which clearly excites management will also excite us and the general investment community now near term opex has been addressed a couple week ago.
2 weeks to go...
KZA Price at posting:
40.0¢ Sentiment: Buy Disclosure: Held
